<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04803539</url>
  </required_header>
  <id_info>
    <org_study_id>SunYatsenU2H-LQ4</org_study_id>
    <nct_id>NCT04803539</nct_id>
  </id_info>
  <brief_title>A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After Adjuvant Chemotherapy in TNBC</brief_title>
  <acronym>Artemis</acronym>
  <official_title>A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After Adjuvant Chemotherapy in TNBC (Artemis)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Circulating tumor DNA (ctDNA) has been demonstrated to be an effective prognostic marker in&#xD;
      breast cancer. Various studies have shown that early TNBC breast cancer patients with&#xD;
      positive ctDNA have high risk of cancer recurrence and worse prognosis. This study aimed to&#xD;
      identify TNBC patients with positive ctDNA and initiate boost therapy in these high risk&#xD;
      patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2021</start_date>
  <completion_date type="Anticipated">September 1, 2033</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2028</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Invasive Disease Free Survival(IDFS)</measure>
    <time_frame>60 months</time_frame>
    <description>Invasive Disease-Free Survival for capecitabine versus capecitabine + apatinib + camrelizumab in ctDNA-positive stage II-III TNBC patients, using STEEP criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Distant disease-free survival(DDFS)</measure>
    <time_frame>60 months</time_frame>
    <description>Distant Disease-Free Survival for capecitabine versus capecitabine + apatinib + camrelizumab in ctDNA-positive stage II-III TNBC patients, using STEEP criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>60 months</time_frame>
    <description>Overall Survival for capecitabine versus capecitabine + apatinib + camrelizumab in ctDNA-positive stage II-III TNBC patients, using STEEP criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brain metastasis rate</measure>
    <time_frame>60 months</time_frame>
    <description>Brain metastasis rate for capecitabine versus capecitabine + apatinib + camrelizumab in ctDNA-positive stage II-III TNBC patients, using STEEP criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of adverse effects(AEs)</measure>
    <time_frame>60 months</time_frame>
    <description>AEs related to apatinib and/or camrelizumab</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Capecitabine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients assigned to this group will receive oral capecitabine at a dose of 650 mg/m2 twice a day by mouth for 1 year</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Capecitabine + Apatinib + Camrelizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients assigned to this group will receive oral capecitabine at a dose of 650 mg/m2 twice a day, Camrelizumab 200mg intravenously, once every two weeks (Q2W), oral apatinib, 250mg, PO, qd for 1 year</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine</intervention_name>
    <description>capecitabine is proved to improve 5-year disease-free survival among women with early-stage triple-negative breast cancer who received standard adjuvant treatment(The SYSUCC-001 Randomized Clinical Trial)</description>
    <arm_group_label>Capecitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine + camrelizumab + apatinib</intervention_name>
    <description>Camrelizumab combined with apatinib is a safe and effective combination proved in patients with advanced TNBC in our early study</description>
    <arm_group_label>Capecitabine + Apatinib + Camrelizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient is ≥ 18 years-old at the time of consent to participate this trial&#xD;
&#xD;
          -  Stage II - III primary triple negative breast cancer patients(TNBC), TNBC is defined&#xD;
             as ER &lt;=1%, PR &lt;=1%；HER2 receptor IHC=1, or IHC=2 and FISH negative.&#xD;
&#xD;
          -  positive ctDNA after curative surgery and/or adjuvant chemotherapy&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
          -  If indicated, patient agree to receive adjuvant radiotherapy according to the&#xD;
             institutional guidelines&#xD;
&#xD;
          -  Patient receives adjuvant chemotherapy according to the NCCN guidelines&#xD;
&#xD;
          -  Patient has available tumor tissue from the surgical specimen for next generation&#xD;
             sequencing(NCS)&#xD;
&#xD;
          -  Patient agrees to give blood samples for ctDNA tests every 3 months in 5 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient has previously received any PD1/PDL1 blockage treatment&#xD;
&#xD;
          -  Pregnant or breast-feeding (lactating) women or women who plan to become pregnant or&#xD;
             breast-feed during the trial&#xD;
&#xD;
          -  Patient with distant metastases of breast cancer beyond regional lymph nodes (stage IV&#xD;
             according to AJCC 8th edition)&#xD;
&#xD;
          -  Patient participates another interventional clinical trial&#xD;
&#xD;
          -  Patient has a concurrent invasive malignancy or a prior invasive malignancy whose&#xD;
             treatment was completed within 3 years before randomization&#xD;
&#xD;
          -  Patient with autoimmune disease preventing the use of camrelizumab&#xD;
&#xD;
          -  Patient has any other concurrent severe and/or uncontrolled medical condition that&#xD;
             would, in the Investigator's judgment, cause unacceptable safety risks, contraindicate&#xD;
             patient participation in the clinical trial or compromise compliance with the protocol&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qiang Liu, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sunyat-sen Memorial Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shunying Li, MD</last_name>
    <phone>86-020-34071156</phone>
    <email>lishunying@foxmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Qiang Liu, PhD</last_name>
    <phone>86-020-34071157</phone>
    <email>victorlq@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sunyat-sen Memorial Hospital</name>
      <address>
        <city>Guandong</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 16, 2021</study_first_submitted>
  <study_first_submitted_qc>March 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 17, 2021</study_first_posted>
  <last_update_submitted>March 16, 2021</last_update_submitted>
  <last_update_submitted_qc>March 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</investigator_affiliation>
    <investigator_full_name>Liu Qiang</investigator_full_name>
    <investigator_title>M.D, PhD</investigator_title>
  </responsible_party>
  <keyword>stage II-III</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Apatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

